药品临床综合评价中MCDA赋权方法比较

Comparison of MCDA weighting techniques in clinical comprehensive evaluation

2022年,国家药物和卫生技术综合评估中心会同有关单位制定心血管病、儿童药品及抗肿瘤药品的临床综合评价技术指南试行版本,均提出可通过多准则决策分析对药品的综合价值进行排序,帮助决策者在多种准则中做出取舍,从而确定最佳选择。同时,指南提及多准则决策分析过程中可能用到的赋权方法,但未进行深入介绍。该文对指南提及的赋权方法的操作步骤及特点进行简单梳理,希望能以此促进多准则决策分析在我国药品临床综合评价过程中的应用,从而形成适合我国国情的药品临床综合评价多准则决策分析方法。

In 2022,The National Center for Comprehensive Assessment of Drug and Health Technology,in collaboration with relevant units,developed three technical guidelines for clinical comprehensive evaluation(for trial)of cardiovascular diseases,pediatric drugs and antineoplastic drugs,respectively.All guidelines mention that multi-criteria decision analysis(MCDA)can be used to rank the comprehensive value of drugs and help decision makers to make trade-offs among multiple criteria to determine the best choice.At the same time,the guidelines mention,but do not go into depth,the weighting techniques that may be used in the MCDA process.This paper briefly composed the operational steps and characteristics of weighting techniques mentioned in the guidelines,hoping to promote the application of MCDA in the process of drugs clinical comprehensive evaluation in China and to form a MCDA method suitable for China's national conditions.